WALLDORF — SAP SE (NYSE: SAP) today announced that the European Medicines Verification Organization (EMVO), the nonprofit dedicated to keeping the pharmaceutical supply chain free from counterfeit medicines, has certified SAP Information Collaboration Hub for Life Sciences, marking a critical step toward meeting regulatory patient safety requirements set for 2019.
The collaboration hub successfully passed the certification test for loading data from marketing authorization holders to the European Hub, the central reporting destination for all prescription medications as required under the EU Falsified Medicines Directive (FMD). The test covered a range of messages, such as product master data, product pack data, product pack data updates and product pack verifications, which manufacturers and distributors are required to submit.
SAP Information Collaboration Hub for Life Sciences facilitates message routing, verification and connectivity. The hub evolved from a pharmaceutical network developed by SAP and a host of large pharmaceutical manufacturers and wholesalers, including Boehringer Ingelheim and AmerisourceBergen. The SAP Advanced Track and Trace for Pharmaceuticals application, an enterprise-scale track and trace repository for the pharmaceutical industry, is integrated into the hub and manages correct message content and related business process handling.
“In our ongoing effort to safeguard patient health, the certification received from EMVO is a major milestone for SAP,” Lori Mitchell-Keller, SAP global general manager for Consumer Industries, said. “The recent certification for the EU market delivers on SAP’s promise to enable compliance with the FMD requirement to ensure patient safety by February 2019.”
Stacy Ries, +1 (484) 619-0411, email@example.com, ET
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2018 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see http://www.sap.com/corporate-en/legal/copyright/index.epx#trademark for additional trademark information and notices.